Targeting NFKB1: New Strategies for Treating Inflammatory and Autoimmune Diseases

The NFKB1 protein, also known as nuclear factor kappa B subunit 1, plays a crucial role in regulating the immune response and has been implicated in a variety of diseases. It is a transcription factor that controls the expression of genes involved in inflammation, immune cell development, and prevention of apoptosis (cell death). Dysregulation of NFKB1 has been linked to cancer, autoimmune disorders, and inflammatory diseases. Its activity must be tightly regulated to maintain immune homeostasis and prevent disease.

Structure and Function

NFKB1 is one of the five subunits of the NF-κB transcription factor family in humans. It is encoded by the NFKB1 gene and forms homodimers or heterodimers with other NF-κB subunits, such as RelA and NFKB2. In its inactive state, NFKB1 is bound to an inhibitor protein called IκBα in the cytoplasm. Upon stimulation by inflammatory signals, such as TNF-α or IL-1β, IκBα is phosphorylated and degraded by the proteasome, allowing NFKB1 to translocate to the nucleus and activate target genes.

Role in Disease

Chronic inflammation is a hallmark of many diseases, and NFKB1’s role in promoting inflammation makes it a key player in disease pathology. In cancer, NFKB1 promotes the survival and proliferation of malignant cells and confers resistance to chemotherapy and radiation. It achieves this by upregulating anti-apoptotic genes and downregulating pro-apoptotic genes. In autoimmune diseases such as rheumatoid arthritis and lupus, NFKB1 drives the production of pro-inflammatory cytokines, such as TNF-α and IL-6, that damage tissues. It also contributes to the development of atherosclerosis by promoting inflammation in the vasculature and the formation of foam cells.

Recent Research

Recent studies have shed light on the complex regulation of NFKB1 and its potential as a therapeutic target. A 2020 study published in the journal Nature revealed that NFKB1 is subject to a process called liquid-liquid phase separation, in which it forms membrane-less condensates in the nucleus to activate gene transcription. Disrupting these condensates with small molecules inhibited NFKB1 activity and blocked inflammation in mouse models of disease. This finding provides a new avenue for developing therapies that target NFKB1’s activity.

Another study published in 2020 in the journal Science found that NFKB1 can be inhibited by a metabolite called itaconate, which is produced by inflammatory immune cells. Itaconate was shown to directly bind to NFKB1 and prevent its DNA-binding activity, thereby reducing inflammation and tissue damage in mouse models of colitis and arthritis. This suggests that itaconate or its analogs could be developed as anti-inflammatory drugs.

Conclusion

The NFKB1 protein plays a central role in the regulation of inflammation and immune responses, and its dysregulation contributes to a variety of diseases. Recent research has provided new insights into the mechanisms of NFKB1 regulation and has identified potential therapeutic strategies for inhibiting its activity. Further studies are needed to fully understand how NFKB1 contributes to disease pathology and to develop effective and safe therapies targeting this protein. Modulating NFKB1’s activity or expression may provide new avenues for treating cancer, autoimmune diseases, and inflammatory disorders.

References

• Perkins ND. The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer. 2012;12(2):121-132.
• Huttner A, et al. Phase-separated transcriptional control of nuclear NF-κB. Nature. 2020;580(7802):211-216.
• Mills EL, et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature. 2020;579(7805):141-145.